       Document 0501
 DOCN  M9620501
 TI    Quantitative measures of human immunodeficiency virus-specific
       antibodies predict progression to AIDS.
 DT    9602
 AU    Strathdee SA; Frank JW; McLaughlin J; Leblanc M; Major C; O'Shaughnessy
       MV; Read SE; British Columbia Centre for Excellence in HIV/AIDS,
       Vancouver,; Canada.
 SO    J Infect Dis. 1995 Nov;172(5):1375-9. Unique Identifier : AIDSLINE
       MED/96036402
 AB    Studies examining specific antibodies directed against antigenic
       components of human immunodeficiency virus (HIV), as potential markers
       of progression to AIDS, have reported inconsistent results. We used
       reflectance densitometry and survival analysis to determine whether
       single quantitative measures of HIV-specific antibodies predicted
       progression to AIDS in a prospective cohort of 159 HIV-infected
       homosexual men. Lowered baseline levels of p24 antibody and p24/gp41
       antibody ratio were independent predictors of progression to AIDS and
       retained statistical significance after simultaneously controlling for
       CD4:CD8 ratio, age, use of zidovudine, and clinical symptoms.
       Quantitative measures of p24 antibody and p24/gp41 antibody ratio
       warrant further study with regards to their clinical application as
       markers of HIV disease progression.
 DE    Acquired Immunodeficiency Syndrome/IMMUNOLOGY/*PHYSIOPATHOLOGY  Adult
       Age Factors  Analysis of Variance  Bisexuality  Comparative Study
       CD4-CD8 Ratio  Disease Progression  Follow-Up Studies  Homosexuality,
       Male  Human  HIV Antibodies/*BLOOD  HIV Core Protein p24/IMMUNOLOGY  HIV
       Envelope Protein gp41/IMMUNOLOGY  HIV
       Infections/BLOOD/IMMUNOLOGY/*PHYSIOPATHOLOGY  HIV
       Seropositivity/BLOOD/IMMUNOLOGY/*PHYSIOPATHOLOGY  Male  Multivariate
       Analysis  Predictive Value of Tests  Prognosis  Support, Non-U.S. Gov't
       Time Factors  Zidovudine/THERAPEUTIC USE  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

